$69 postpage LB

Pfizer COVID-19 Vaccine Rollout Restricted in Australia Amid Supply Concerns

  • January 14, 2021 05:45 PM AEDT
  • Kunal Sawhney
    CEO Kunal Sawhney
    2212 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

Pfizer COVID-19 Vaccine Rollout Restricted in Australia Amid Supply Concerns

Summary

  • The CMO of Australia, Mr Paul Kelly, stated that the Australian federal government is unable to secure more doses of the Pfizer-BioNTech’s COVID-19 vaccine.
  • During the negotiations, Brooklyn-based Pfizer offered almost 10 million doses to the Australian government, due to be delivered.
  • Oxford-AstraZeneca’s vaccine would be made available in the market once the TGA gives a green light.
Gold MTF non-AMP

Australia is in negotiations with US pharma giant Pfizer Inc and several other vaccine manufacturers hoping to secure more COVID-19 vaccine contracts. However, according to some media reports, the Australian government has not been able to get more doses from Pfizer despite multiple discussions. Meanwhile, a section of health experts emphasises that the current vaccine reserves are already good enough to save the lives of many Aussies.

Let us deep dive and discuss in detail-

Pfizer’s COVID-19 vaccine out of reach for Australians

Australia’s CMO Paul Kelly stated that the Australian federal government is unable to ensure more doses of the Pfizer Inc (NYSE:PFE)-BioNTech SE’s (Nasdaq:BNTX) COVID-19 vaccine. However, health officials reassure Australians that the vaccine manufactured by Oxford University and AstraZeneca Plc (LON:AZN) will protect them.

Moreover, the rising concern of whether the country should be using Pfizer-BioNTech’s vaccine is ultimately answered as it is not available readily. In the negotiations with the New York-headquartered pharmaceutical giant, Pfizer offered almost 10 million doses to the Australian government, due to be delivered.

Besides, there is the potential to obtain more vaccines via the COVAX agreement. However, there is no certainty that it will happen.

Advantages of Oxford-AstraZeneca’s vaccine to Australians

A considerable advantage of the Oxford-AstraZeneca COVID-19 vaccine is that it is manufactured in Australia. The vaccine will be available after the Therapeutic Goods Administration (TGA) gives its green light, which the country anticipates in February 2021.

    ©Kalkine Group 2021

CMO Paul Kelly stated that the Oxford-AstraZeneca vaccine is a high-quality vaccine and is effective and safe. The Australian regulatory body will be looking at these factors with their full approval coming shortly.

Besides, the Australian government has signed supply agreements for the vaccine with AstraZeneca, Pfizer and Novavax.

Concerns over Herd Immunity

Many Australian experts are worried about the COVID-19 vaccine developed by Oxford University and AstraZeneca, worried that it may not be effective enough to attain herd immunity.

CMO Paul Kelly responds to debate over the Oxford-AstraZeneca’s COVID-19 vaccine saying the country is choosing a vaccine that saves lives and is accessible for the full rollout.

Meanwhile, commenting on herd immunity, some experts say that there is a way for it by using both the Oxford-AstraZeneca and Pfizer-BioNTech vaccines.

READ MORE: Australia’s CMO backs Oxford-AstraZeneca COVID-19 vaccine amid efficacy concerns

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK